The 2022 Tandem Meetings | Approval of axi-cel in second-line for R/R LBCL & label update
Evandro Bezerra
• 23 Apr 2022
Evandro Bezerra, MD, Mayo Clinic, Rochester, MN, gives an update on the use of axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL). In January 2022, the FDA approved a new label update for axi-cel allowing the use of prophylactic dexamethasone to limit CAR-T toxicity. In addition, following the positive results of the ZUMA-7 (NCT03391466) and TRANSFORM (NCT03575351) trials, the FDA approved axi-cel in patients with primary refractory disease in April 2022. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
